



Cite this: *Chem. Commun.*, 2025, 61, 3375

Received 6th January 2025,
Accepted 27th January 2025


DOI: 10.1039/d5cc00090d

rsc.li/chemcomm

This manuscript describes the development of difunctional alkenyl boronates that contain an oxidatively releasable cargo and an amine for attaching to groups that can improve physical properties or enhance cellular targeting. The design is applied to a FRET-based system that delivers a selective fluorescence response in oxidatively stressed cells.

Numerous medical conditions, including cancer, arthritis, neurodegeneration, viral infection, diabetes, and reperfusion injury, lead to oxidatively stressed cells.¹ Oxidative stress results in heightened concentrations of hydrogen peroxide, which can be exploited for the release of probes or drugs from boron-containing precursors.² Borylated benzylic carbamates and carbonates, which undergo a 1,6-elimination upon reacting with H₂O₂, have been utilized extensively for this purpose, as illustrated (Scheme 1) by the oxidation of **1** to release the positron emitting tomography probe **2** along with quinone methide **3**.³ We have developed alternatives to the borylated benzylic group to promote oxidative release, with the borylated allyloxy (BAO) group releasing compounds through a 1,4-elimination⁴ and the α -boryl ether promoting oxidative 1,2-elimination.⁵ These species show heightened reactivity in comparison to benzylic variants, thereby allowing for their attachment through stable ether and acetal linkages. The peroxide-mediated cleavage of **4** to release the pederin analogue **5** and acrolein (**6**) provides a powerful example of the utility of the design.^{4c} Compound **4** is a potent cytotoxin toward cancer cell lines while being far less toxic toward non-cancerous cells and acrolein, when released through a slow, controlled oxidative cleavage, proved to be non-toxic.


The selectivity that results from using boron-containing prodrugs might be enhanced by incorporating an additional



Scheme 1 Probe and drug release through boronate oxidation. EPin = tetraethyl pinacol.

functional group that could be used for attachment to antibodies,⁶ nanoparticles,⁷ or cell delivery agents.⁸

Difunctionalized arylboronates have been reported by Shabat⁹ for oxidative signal amplification through dendrimer breakdown, and by Spring,¹⁰ who reported an oxidatively labile antibody-directed conjugate. We became intrigued by the possibility of increasing the functional group content on the BAO subunit to enhance its utility while retaining its high oxidative cleavage rate. BAO groups can be functionalized (Scheme 2) on



Scheme 2 Oxidative carbon–oxygen bond cleavage from functionalized BAO groups. R can be a cell-targeting group, R'OH can be a drug or biological probe.

Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA. E-mail: floean@pitt.edu

† Electronic supplementary information (ESI) available: Synthetic protocols, characterization data, fluorescence studies, cellular assays, and ¹H, ¹¹B, and ¹³C NMR spectra. See DOI: <https://doi.org/10.1039/d5cc00090d>

‡ Current address: Department of Chemistry, Princeton University, USA.




the alkene, where **7** will release an alcohol and form **8**, or at the allylic position, where **9** will release the alcohol and **10**.


This manuscript describes the synthesis of difunctionalized BAO groups inspired by **7** and **9**, and their functionalization with a FRET pair. The peroxide-mediated cleavage of these molecules leads to a time-dependent fluorescence response. Cellular studies show that these probes can distinguish oxidatively stressed cancer cell lines from non-cancerous cells. Cleavage in non-cancerous cells can be initiated through the addition of exogenous H_2O_2 .

The synthesis of the vinyl-substituted linker is shown in Scheme 3. Hydroxymethylation of 6-chloro-1-hexyne (**11**) followed by chloride displacement by phthalimide provides propargylic alcohol **12**. Removal of the phthalate group and sulphonylation with dansyl chloride provides the fluorescent sulphonamide **13**. Hydroboration under Carretero's conditions¹¹ produced vinyl boronate **14**. Acylation of **14** proved to be unexpectedly challenging due to the electron-withdrawing effect of the boronate group, though Katritzky's acyl benzotriazole reagent **15**¹² proved to be an excellent agent to complete the synthesis of the fluorophore-quencher paired ester **16**.

Substitution at the allylic position offers additional possibilities for linker synthesis, including cross-metathesis^{4c,13} or alkyne hydroboration, in cases where a substrate is not compatible with copper-mediated borylation. The synthesis of the allylic-substituted linker is shown in Scheme 4. Sulphonylation of 6-amino-1-hexanol (**17**) with dansyl chloride provided the fluorescent sulphonamide **18**. A Swern oxidation followed by the addition of lithium trimethylsilyl acetylidyne followed by silyl cleavage produced propargyl alcohol **19**. Acylation with **15** and a subsequent hydroboration with pinacol borane in the presence of $\text{Cp}_2\text{Zr}(\text{H})\text{Cl}$ ¹⁴ completed the synthesis of **20**.




Scheme 3 Synthesis of a vinyl-substituted oxidatively cleavable latent fluorophore.



Scheme 4 Synthesis of an allylic-substituted latent fluorophore.

The oxidative release of compounds **16** and **20** was initially monitored by ^1H NMR spectroscopy (Scheme 5). Compound **16** was dissolved in DMSO-d6 and pH = 7.4 buffer and compound **20** was dissolved in CD_3CN and pH = 7.4 buffer (1 mM final concentration for both) and treated with H_2O_2 -urea (30 equiv.) at 37 °C. Compound **16** reacted to completion within 10 min to form **21** in 89% yield, as determined by comparison to an internal standard, along with acid **22**. Similarly, **20** reacted to completion in 11 min to form **23** in 90% yield accompanied by **22**. The negative



Scheme 5 Oxidative release of the latent fluorophores monitored by ^1H NMR.



control compound **24** was unreactive toward the reaction conditions, thereby confirming that the cleavage was dependent upon boronate oxidation.

results of the NMR study led us to pursue a fluorescence-based assay to confirm that these processes could be viable at lower substrate and peroxide concentrations. Exposing **16** (final concentration = 200 μ M) to H_2O_2 ·urea (30 equiv.) in DMSO and pH = 7.4 buffer at 37 °C showed a time-dependent increase in fluorescence until reaching a maximum within 3 h (Fig. 1A). A few aspects of this study were notable. Compound **21** showed an upward drift over time, which could arise from enone oxidation (see below). The fluorescence intensity did not meet the values that were seen from a 200 μ M solution of **21**, and the curve changes its shape at approximately 45% conversion. However when we tested the fluorescence intensity of a 1:1 mixture of **21** and **22** (200 μ M of each) we observed good agreement with the maximum that was achieved in the release experiment. This indicates that bimolecular quenching accounts for the discrepancies from the initially expected results. Further evidence for intermolecular quenching arose from a variation on Blackmond's similar ["excess"] experiment¹⁵ in which the experiment commenced with 111 μ M **16** and 91 μ M **21** (the approximate concentrations of each at the point of the reaction in which the curve shape changed). This experiment showed a higher final fluorescence intensity, supporting our hypothesis of intermolecular quenching by **21**. No release was observed from **24** in the presence of H_2O_2 or from **16** in the absence of H_2O_2 .

The cleavage of **20** also proceeded efficiently, showing a similar pattern to the cleavage of **16**. Identifying a precise time




Fig. 1 Fluorescence intensity of **16** (A) and **20** (B) in the presence (+) and absence (−) of H_2O_2 (6 mM) in DMSO and pH 7.4 buffer (200 μ M initial substrate concentration) at 37 °C. The excitation wavelength was 335 nm and the emission wavelength was 534 nm.

for complete release was not possible because the independently synthesized α,β -unsaturated aldehyde **23** showed an increase in fluorescence under the cleavage conditions. We postulate that the enal partially quenches fluorescence from the dansyl, in analogy to studies showing fluorescence quenching by unsaturated carbonyl groups.¹⁶ Prolonged exposure to H_2O_2 can result in nucleophilic epoxidation and a reduction in quenching. Epoxidation can occur under the cleavage conditions and that the epoxide shows no drift in a fluorescence study under the reaction conditions.¹⁷

Our previous study of oxidatively cleavable pederin-based prodrugs guided our selection of cell lines for monitoring *in vitro* fluorophore release. The previous study showed that the prodrug required exogenous H_2O_2 in non-cancerous HEK293T cells to promote a cytotoxic response, promoted a moderate cytotoxic response in U87 glioblastoma cells that was enhanced by exogenous H_2O_2 , and was potently cytotoxic in B16 melanoma cells in the absence or presence of exogenous H_2O_2 . We hypothesized that this trend correlated with the levels of endogenous H_2O_2 in the cells, with stronger cytotoxic responses correlating to higher peroxide concentrations.

The results of the cellular studies are shown in Fig. 2. We selected compound **16** for these studies with compound **24** as the




Fig. 2 Fluorescence response of cells to **16** and **24**. Cells were incubated with the compound in media (20 μ M) for 45 min at 37 °C, then the media was removed and replaced either with buffer (−) or a solution of H_2O_2 (+). (A) Images of cells after being exposed to **16** or **24** for 45 min. Fluorescence was imaged on a Zeiss Axio Observer Z1 using a 40x objective and DAPI (Chroma filter 49028) filter ($\lambda_e = 395$ nm, $\lambda_m = 460$ nm). Gray images are brightfield. (B) Relative responses of the cells after being exposed to **16** and **24** after 45 min in the absence and presence of exogenous H_2O_2 . See the ESI† for details on the calculations of relative fluorescence. (C) Comparison of the relative fluorescence for the cell lines in the absence of exogenous H_2O_2 . * = $P < 0.05$, ** = $P < 0.001$, *** = $P < 0.005$, ns = not statistically different.

negative control. The cells were exposed to solutions of **16** or **24** in media (20 μ M) for 45 min, then the media was exchanged with PBS buffer containing either H_2O or H_2O_2 (100 μ M). The responses of the cells were observed after an additional 45 min incubation through a DAPI filter that allows for absorption at 395 nm and emission at 460 nm. These wavelengths are not ideal for observing the release of **21**, which has an absorption λ_{max} of 330 nm and an emission λ_{max} of 500 nm. Despite the non-optimal wavelengths for absorption and emission and the relatively short incubation times, we observed notable fluorescence in U87 and B16 cells in the absence of exogenous H_2O_2 (Fig. 2A, images were pseudocolored to cyan). As expected, the response appeared stronger upon the addition of H_2O_2 , though the large error in the peroxide treated B16 cells rendered the difference statistically non-significant (Fig. 2B). Fluorescence was not visible in HEK cells in the absence of added H_2O_2 but appeared when H_2O_2 was added, indicating that the lack of an inherent fluorescent response did not result from **16** being impermeable in these cells.

The negative control **24** produced no fluorescence in any cell line, which is consistent with the cleavages being initiated by peroxide rather than a non-specific process. This allowed for a quantitative comparison of the responses of the different cell lines toward **16** against their responses to **24** (Fig. 2B). Although the fluorescence in the response of HEK cells in the absence of exogenous H_2O_2 was not visually apparent, a minor response was detected through imaging. This is expected since most cells produce at least low concentrations of H_2O_2 .¹⁸ Oxidative stress also leads cells to produce low levels of hypochlorite and peroxynitrite,¹⁹ and these agents are significantly more effective at boronate oxidation than H_2O_2 .²⁰ Therefore the responses could be augmented by the actions of these agents, though the use of DMSO as a co-solvent for the studies reduces hypochlorite.²¹ The responses of the U87 and B16 cells were approximately equivalent and notably higher than the response of the HEK cells (Fig. 2C).

We have shown the synthesis and peroxide-mediated cleavage of two difunctional vinyl boronate linkers that are suitable for drug delivery and release applications. Differential functionalization of the linkers is facile, as demonstrated by the attachment of the dansyl/dabcyl FRET pair. NMR studies showed a rapid and efficient cleavage of the vinyl boronates to release the dabcyl group. The cleavage was monitored at sub-millimolar concentrations through fluorescence spectroscopy and confirmed the expected time-dependent loss of quenching. Exposing the boronate-containing FRET pair to oxidatively stressed cancer cells resulted in a substantially greater fluorescent response in comparison to results with non-oxidatively stressed epithelial cells. These results support the capacity to apply the linkers to the synthesis of antibody-drug conjugates, nanoparticles, and cell-permeating agents that utilize oxidative stress for site-selective drug release.

This work was supported by funding from the National Institutes of Health (R01GM127153 to P. E. F. and A. D.,

R01GM140655 to P. E. F., and R01GM145086 to A. D.). G. M. F. was supported through a McKeever Award. S. A. was supported through an Andrew Mellon Predoctoral Fellowship.

Data availability

The data supporting this article have been included as part of the ESI.[†]

Conflicts of interest

There are no conflicts to declare.

Notes and references

- (a) T. P. Szatrowski and C. F. Nathan, *Cancer Res.*, 1991, **51**, 794–798; (b) W. R. Wilson and M. P. Hay, *Nat. Rev. Cancer*, 2011, **11**, 393–410; (c) C. J. Wruck, A. Fragoulis, A. Gurzynski, L.-O. Brandenburg, Y. W. Kan, K. Chan, J. Hassenpflug, S. Freitag-Wolf, D. Varoga, S. Lippross and T. Pufe, *Ann. Rheum. Dis.*, 2011, **70**, 844–850; (d) X. Chen, C. Guo and J. Kong, *Neural Regen. Res.*, 2012, **7**, 376–385; (e) M. Liu, F. Chen, T. Liu, F. Chen, S. Liu and J. Yang, *Microbes Infect.*, 2017, **19**, 580–586; (f) N. Houstis, E. D. Rosen and E. S. Lander, *Nature*, 2000, **400**, 944–948; (g) R. Bolli, M. O. Jeroudi, B. S. Patel, C. M. DuBose, E. K. Lai, R. Roberts and P. B. McCay, *Proc. Natl. Acad. Sci. U. S. A.*, 1989, **86**, 4695–4699.
- (a) M. S. Messina, G. Quargnali and C. J. Chang, *ACS Bio. Med. Chem. Au*, 2022, **2**, 548–564; (b) H. Maslah, C. Skarbek, S. Pethe and R. Labruere, *Eur. J. Med. Chem.*, 2020, **207**, 112670; (c) G. Saravanakumar, J. Kim and W. J. Kim, *Adv. Sci.*, 2017, **4**, 1660214.
- 3 V. Carroll, B. W. Michel, J. Blecha, H. VanBrocklin, K. Keshari, D. Wilson and C. J. Chang, *J. Am. Chem. Soc.*, 2014, **136**, 14742–14745.
- 4 (a) R. A. Mosey and P. E. Floreancig, *Org. Biomol. Chem.*, 2012, **10**, 7980–7985; (b) B. M. Klootwyk, A. E. Ryan, A. Lopez, M. J. R. McCloskey, C. P. Janosko, A. Deiters and P. E. Floreancig, *Org. Lett.*, 2023, **25**, 5530–5535; (c) P. J. Geaneotes, C. P. Janosko, C. Afeke, A. Deiters and P. E. Floreancig, *Angew. Chem., Int. Ed.*, 2024, **63**, e202409229.
- 5 R. D. Hanna, Y. Naro, A. Deiters and P. E. Floreancig, *J. Am. Chem. Soc.*, 2016, **138**, 13353–13360.
- 6 C. Dumontet, J. M. Reichert, P. D. Senter, J. M. Lambert and A. Beck, *Nat. Rev. Drug Discovery*, 2023, **22**, 641–661.
- 7 M. A. Beach, U. Nayanthara, Y. Gao, C. Zhang, Y. Xiong, Y. Wang and G. K. Such, *Chem. Rev.*, 2024, **124**, 5505–5616.
- 8 J. Wang, B. Li, L. Qiu, X. Qiao and H. Yang, *J. Biol. Eng.*, 2022, **16**, 18.
- 9 E. Sella and D. Shabat, *J. Am. Chem. Soc.*, 2009, **131**, 9934–9936.
- 10 N. Ashman, J. D. Bargh, S. J. Walsh, R. D. Greenwood, A. Tiberghien, J. S. Carroll and D. R. Spring, *Chem. Commun.*, 2023, **59**, 1841–1844.
- 11 A. L. Moure, R. G. Arrayás, D. J. Cárdenas, I. Alonso and J. C. Carretero, *J. Am. Chem. Soc.*, 2012, **134**, 7219–7222.
- 12 A. R. Katritzky, Q.-Y. Chen and S. R. Tala, *Org. Biomol. Chem.*, 2008, **6**, 2400–2404.
- 13 C. Morrill and R. H. Grubbs, *J. Org. Chem.*, 2003, **68**, 6031–6034.
- 14 S. Pereira and M. Srebnik, *Organometallics*, 1995, **14**, 3127–3128.
- 15 D. G. Blackmond, *Angew. Chem., Int. Ed.*, 2005, **44**, 4302–4320.
- 16 V. Hong, A. A. Kislyukhin and M. G. Finn, *J. Am. Chem. Soc.*, 2009, **131**, 9986–9994.
- 17 Please see the ESI[†] for details.
- 18 S. M. Kondengadan and B. Wang, *Angew. Chem., Int. Ed.*, 2024, **63**, e202403880.
- 19 C. C. Winterbourne, *Nat. Chem. Biol.*, 2008, **4**, 278–286.
- 20 A. Sikora, J. Zielonka, M. Lopez, J. Joseph and B. Kalanaraman, *Free Radical Biol. Med.*, 2009, **47**, 1401–1407.
- 21 S. Bansal and B. Wang, *Chem. Sci.*, 2024, **15**, 17843–17851.

